<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3066942</article-id><article-id pub-id-type="publisher-id">cc9688</article-id><article-id pub-id-type="doi">10.1186/cc9688</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Atorvastatin for preventing the progression of sepsis to severe sepsis (ASEPSIS Trial): a randomised, double-blind, placebo-controlled trial (ISRCTN64637517)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Patel</surname><given-names>JM</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Snaith</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Thickett</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Linhortova</surname><given-names>L</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Melody</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Hawkey</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Barnett</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Jones</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Hong</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Perkins</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Cooke</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Gao-Smith</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Heart of England NHS Foundation Trust, Birmingham, UK</aff><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>11</day><month>3</month><year>2011</year></pub-date><volume>15</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">31st International Symposium on Intensive Care and Emergency Medicine</named-content><ext-link ext-link-type="uri" xlink:href="http://ccforum.com/supplements/notes/ccv15s1-info.pdf">http://ccforum.com/supplements/notes/ccv15s1-info.pdf</ext-link></supplement><fpage>P268</fpage><lpage>P268</lpage><permissions><copyright-statement>Copyright &#x000a9;2011 Patel et al.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Patel et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/15/S1/P268"/><conference><conf-date>22&#x02013;25 March 2011</conf-date><conf-name>31st International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>Statins have pleiotrophic effects independent of their lipid-lowering properties and may modulate the pathophysiology of sepsis, prevent sepsis progression and improve outcomes [<xref ref-type="bibr" rid="B1">1</xref>]. This study evaluated the acute use of Atorvastatin in reducing sepsis progression compared with placebo in statin-naive individuals.</p></sec><sec sec-type="methods"><title>Methods</title><p>A single-centre, randomised placebo-controlled, double-blind trial (RCT). Ethical approval and consents were obtained. Patients with sepsis, based on the Surviving Sepsis Campaign Guidelines (SSCG), were randomised to Atorvastatin 40 mg daily or placebo for length of hospital stay or 28 days if earlier. Patients on statins were excluded. Primary outcome was progression to severe sepsis, defined by the SSCG.</p></sec><sec><title>Results</title><p>One hundred patients were consented and randomised, 49 to Atorvastatin and 51 to placebo. Both were well matched for all baseline characteristics. The Atorvastatin group had a lower rate of sepsis progression <italic>P </italic>= 0.007 (Figure <xref ref-type="fig" rid="F1">1</xref>). The 28-day and 1-year mortalities were similar with an overall 12% mortality. There was no difference in 28-day readmissions (<italic>P </italic>= 0.83); however, 1-year readmissions were higher in the placebo group (<italic>P </italic>&#x0003c; 0.001). A rise in matrix metallopeptidase 9 (<italic>P </italic>= 0.01) at day 4 was observed in the Atorvastatin group.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Percentage of patients progressing to severe sepsis (%)</bold>.</p></caption><graphic xlink:href="cc9688-1"/></fig></sec><sec><title>Conclusions</title><p>This is the first RCT to show that the acute use of Atorvastatin can prevent sepsis progression in statin-naive individuals. A multicentred RCT is required to elucidate the mechanisms and clinical applications of these findings.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="other"><name><surname>Janda</surname><given-names>S</given-names></name><etal/><source>J Crit Care</source><year>2010</year><volume>25</volume><fpage>656e7</fpage><lpage>656e22</lpage></mixed-citation></ref></ref-list></back></article>